Salud financiera de hoja de balance de Aurobindo Pharma
Salud financiera controles de criterios 5/6
Aurobindo Pharma tiene un patrimonio de accionistas total de ₹308.8B y una deuda total de ₹80.9B, lo que sitúa su ratio deuda-patrimonio en 26.2%. Sus activos y pasivos totales son ₹480.9B y ₹172.1B respectivamente. El BAIT de Aurobindo Pharma es de ₹49.8B, por lo que su ratio de cobertura de intereses es de 63.2. Tiene efectivo e inversiones a corto plazo que ascienden a ₹68.7B.
Información clave
26.2%
Ratio deuda-patrimonio
₹80.91b
Deuda
| Ratio de cobertura de intereses | 63.2x |
| Efectivo | ₹68.68b |
| Patrimonio | ₹308.85b |
| Total pasivo | ₹172.09b |
| Activos totales | ₹480.94b |
Actualizaciones recientes sobre salud financiera
Here's Why Aurobindo Pharma (NSE:AUROPHARMA) Can Manage Its Debt Responsibly
Jun 20
Aurobindo Pharma (NSE:AUROPHARMA) Has A Pretty Healthy Balance Sheet
Dec 27Is Aurobindo Pharma (NSE:AUROPHARMA) A Risky Investment?
Jun 14Aurobindo Pharma (NSE:AUROPHARMA) Seems To Use Debt Quite Sensibly
Jan 09We Think Aurobindo Pharma (NSE:AUROPHARMA) Can Stay On Top Of Its Debt
Jun 20Recent updates
Earnings Miss: Aurobindo Pharma Limited Missed EPS By 14% And Analysts Are Revising Their Forecasts
Nov 12Insufficient Growth At Aurobindo Pharma Limited (NSE:AUROPHARMA) Hampers Share Price
Oct 20Estimating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)
Sep 10This Is Why Aurobindo Pharma Limited's (NSE:AUROPHARMA) CEO Can Expect A Bump Up In Their Pay Packet
Aug 23Earnings Update: Here's Why Analysts Just Lifted Their Aurobindo Pharma Limited (NSE:AUROPHARMA) Price Target To ₹1,422
Aug 13Here's Why Aurobindo Pharma (NSE:AUROPHARMA) Can Manage Its Debt Responsibly
Jun 20Aurobindo Pharma Limited (NSE:AUROPHARMA) Released Earnings Last Week And Analysts Lifted Their Price Target To ₹1,271
May 29Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value
May 22Aurobindo Pharma Limited's (NSE:AUROPHARMA) Earnings Are Not Doing Enough For Some Investors
Apr 10Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Worth ₹1.1k Based On Its Intrinsic Value?
Jan 14Aurobindo Pharma (NSE:AUROPHARMA) Has A Pretty Healthy Balance Sheet
Dec 27Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value
Sep 07Is Aurobindo Pharma (NSE:AUROPHARMA) A Risky Investment?
Jun 14Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Trading At A 29% Discount?
May 21Aurobindo Pharma Limited's (NSE:AUROPHARMA) Intrinsic Value Is Potentially 93% Above Its Share Price
Feb 11Aurobindo Pharma (NSE:AUROPHARMA) Seems To Use Debt Quite Sensibly
Jan 09Is There An Opportunity With Aurobindo Pharma Limited's (NSE:AUROPHARMA) 50% Undervaluation?
Nov 02We Think Aurobindo Pharma (NSE:AUROPHARMA) Can Stay On Top Of Its Debt
Jun 20Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo (₹262.3B) de AUROPHARMA superan a sus pasivos a corto plazo (₹143.4B).
Pasivo a largo plazo: Los activos a corto plazo de AUROPHARMA (₹262.3B) superan a sus pasivos a largo plazo (₹28.7B).
Historial y análisis de deuda-patrimonio
Nivel de deuda: El ratio deuda neta-patrimonio (4%) de AUROPHARMA se considera satisfactorio.
Reducción de la deuda: El ratio deuda-patrimonio de AUROPHARMA ha pasado de 37.2% a 26.2% en los últimos 5 años.
Cobertura de la deuda: La deuda de AUROPHARMA no está bien cubierta por el flujo de caja operativo (19.6%).
Cobertura de intereses: Los pagos de intereses de la deuda de AUROPHARMA están bien cubiertos por el BAIT (63.2x cobertura).